View Item 

Show simple item record

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
dc.contributor.authorLv, Jia‐wei
dc.contributor.authorQi, Zhen‐yu
dc.contributor.authorZhou, Guan‐qun
dc.contributor.authorHe, Xiao‐jun
dc.contributor.authorChen, Yu‐pei
dc.contributor.authorMao, Yan‐ping
dc.contributor.authorChen, Lei
dc.contributor.authorTang, Ling‐long
dc.contributor.authorLi, Wen‐fei
dc.contributor.authorLin, Ai‐hua
dc.contributor.authorMa, Jun
dc.contributor.authorSun, Ying
dc.date.accessioned2018-03-07T18:23:20Z
dc.date.available2019-05-13T14:45:23Zen
dc.date.issued2018-03
dc.identifier.citationLv, Jia‐wei ; Qi, Zhen‐yu ; Zhou, Guan‐qun ; He, Xiao‐jun ; Chen, Yu‐pei ; Mao, Yan‐ping ; Chen, Lei; Tang, Ling‐long ; Li, Wen‐fei ; Lin, Ai‐hua ; Ma, Jun; Sun, Ying (2018). "Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy." Cancer Science 109(3): 751-763.
dc.identifier.issn1347-9032
dc.identifier.issn1349-7006
dc.identifier.urihttps://hdl.handle.net/2027.42/142423
dc.publisherSpringer
dc.publisherWiley Periodicals, Inc.
dc.subject.otherintensityâ modulated radiation therapy
dc.subject.othercumulative cisplatin dose
dc.subject.otherinduction chemotherapy
dc.subject.othernasopharyngeal carcinoma
dc.subject.otherreal world data
dc.titleOptimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142423/1/cas13474_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142423/2/cas13474.pdf
dc.identifier.doi10.1111/cas.13474
dc.identifier.sourceCancer Science
dc.identifier.citedreferenceBerger ML, Lipset C, Gutteridge A, Axelsen K, Subedi P, Madigan D. Optimizing the leveraging of realâ world data to improve the development and use of medicines. Value Health. 2015; 18: 127 â 130.
dc.identifier.citedreferenceTorre LA, Bray F, Siegel RL, Ferlay J, Lortetâ Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87 â 108.
dc.identifier.citedreferenceCao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011; 30: 114 â 119.
dc.identifier.citedreferenceLee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionallyâ advanced nasopharyngeal carcinoma: NPCâ 9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005; 23: 6966 â 6975.
dc.identifier.citedreferenceLee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrentâ adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010; 102: 1188 â 1198.
dc.identifier.citedreferenceCao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017; 75: 14 â 23.
dc.identifier.citedreferenceHui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatinâ radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009; 27: 242 â 249.
dc.identifier.citedreferenceSun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17: 1509 â 1520.
dc.identifier.citedreferenceTan T, Lim WT, Fong KW, et al. Concurrent chemoâ radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015; 91: 952 â 960.
dc.identifier.citedreferenceLee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPCâ 0501 evaluating the therapeutic gain by changing from concurrentâ adjuvant to inductionâ concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015; 121: 1328 â 1338.
dc.identifier.citedreferenceAng KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol. 2004; 22: 4657 â 4659.
dc.identifier.citedreferencePeng H, Chen L, Zhang Y, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial. Oncologist. 2016; 21: 1369 â 1376.
dc.identifier.citedreferenceLoong HH, Ma BB, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012; 104: 300 â 304.
dc.identifier.citedreferencePeng H, Chen L, Li WF, et al. Tumor response to neoadjuvant chemotherapy predicts longâ term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial. Cancer. 2017; 123: 1643 â 1652.
dc.identifier.citedreferenceZhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensityâ modulated radiation therapy versus 2Dâ RT or 3Dâ CRT for the treatment of nasopharyngeal carcinoma: a systematic review and metaâ analysis. Oral Oncol. 2015; 51: 1041 â 1046.
dc.identifier.citedreferenceLai SZ, Li WF, Chen L, et al. How does intensityâ modulated radiotherapy versus conventional twoâ dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011; 80: 661 â 668.
dc.identifier.citedreferenceTran B, Keating CL, Ananda SS, et al. Preliminary analysis of the costâ effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data. Intern Med J. 2012; 42: 794 â 800.
dc.identifier.citedreferenceAmin MB, Edge S, Green F, et al. AJCC Cancer Staging Manual, 8th edn. New York: Springer; 2016.
dc.identifier.citedreferenceAustin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using manyâ toâ one matching on the propensity score. Am J Epidemiol. 2010; 172: 1092 â 1097.
dc.identifier.citedreferenceO’Quigley J, Moreau T. Testing the proportional hazards regression model against some general alternatives. Rev Epidemiol Sante Publique. 1984; 32: 199 â 205.
dc.identifier.citedreferenceLee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrentâ adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPCâ 9901 and NPCâ 9902 Trials. Eur J Cancer. 2011; 47: 656 â 666.
dc.identifier.citedreferenceLi JX, Huang SM, Jiang XH, et al. Local failure patterns for patients with nasopharyngeal carcinoma after intensityâ modulated radiotherapy. Rad Oncol. 2014; 9: 87.
dc.identifier.citedreferenceWolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensityâ modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloanâ Kettering experience. Int J Radiat Oncol Biol Phys. 2006; 64: 57 â 62.
dc.identifier.citedreferenceLin JC, Wang WY, Chen KY, et al. Quantification of plasma Epsteinâ Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461 â 2470.
dc.identifier.citedreferenceChan KC. Plasma Epsteinâ Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer. 2014; 33: 598 â 603.
dc.identifier.citedreferenceAdham M, Greijer AE, Verkuijlen SA, et al. Epsteinâ Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment. Clin Cancer Res. 2013; 19: 2175 â 2186.
dc.identifier.citedreferencePeng H, Chen L, Li WF, et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensityâ modulated radiotherapy: a propensity score matching analysis. Oral Oncol. 2016; 62: 78 â 84.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cas13474_am.pdf
Size:
377.4KB
Format:
PDF
View/Open
Name:
cas13474.pdf
Size:
1.152MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.